HPC
IMDX

HM Payson & Co’s Insight Molecular Diagnostics IMDX Stock Holding History

HM Payson & Co’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed – – 952
2019
Q4 		$0 Hold
7
– – ﹤0.01% 957
2019
Q3 		$0 Hold
7
– – ﹤0.01% 966
2019
Q2 		$0 Buy
+7
New +$582 ﹤0.01% 953

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

HM Payson & Co's IMDX Position: Q1 2020 in Review

HM Payson & Co sold out of Insight Molecular Diagnostics (IMDX) in Q1 2020, closing a stake of 7 shares.

HM Payson & Co first reported a position in IMDX in Q2 2019 and held it in 3 quarters. The position peaked at $0 in Q4 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q1 2020.

  • HM Payson & Co reported no remaining Insight Molecular Diagnostics position as of Q1 2020 after selling out during the quarter.
  • HM Payson & Co sold 7 Insight Molecular Diagnostics shares in Q1 2020.
  • HM Payson & Co first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 3 quarters.
  • HM Payson & Co's Insight Molecular Diagnostics position peaked at $0 in Q4 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2020.

Based on HM Payson & Co's 13F filing for Q1 2020, filed 1 Jul 2020.